CO6741219A2 - Inhibidores de catepsina c - Google Patents

Inhibidores de catepsina c

Info

Publication number
CO6741219A2
CO6741219A2 CO13190045A CO13190045A CO6741219A2 CO 6741219 A2 CO6741219 A2 CO 6741219A2 CO 13190045 A CO13190045 A CO 13190045A CO 13190045 A CO13190045 A CO 13190045A CO 6741219 A2 CO6741219 A2 CO 6741219A2
Authority
CO
Colombia
Prior art keywords
cathepsin
inhibitors
butenamides
amino
formula
Prior art date
Application number
CO13190045A
Other languages
English (en)
Spanish (es)
Inventor
Christopher E Neipp
Michael R Palovich
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6741219(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO6741219A2 publication Critical patent/CO6741219A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO13190045A 2011-02-11 2013-08-09 Inhibidores de catepsina c CO6741219A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11

Publications (1)

Publication Number Publication Date
CO6741219A2 true CO6741219A2 (es) 2013-08-30

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13190045A CO6741219A2 (es) 2011-02-11 2013-08-09 Inhibidores de catepsina c

Country Status (24)

Country Link
US (2) US8841463B2 (enExample)
EP (1) EP2672821B9 (enExample)
JP (1) JP5931929B2 (enExample)
KR (1) KR20140048857A (enExample)
CN (1) CN103491777B (enExample)
AR (1) AR085163A1 (enExample)
AU (1) AU2012214405B2 (enExample)
BR (1) BR112013020510A2 (enExample)
CA (1) CA2827157A1 (enExample)
CL (1) CL2013002325A1 (enExample)
CO (1) CO6741219A2 (enExample)
DO (1) DOP2013000182A (enExample)
EA (1) EA023168B1 (enExample)
ES (1) ES2583091T3 (enExample)
IL (1) IL227814A0 (enExample)
MA (1) MA34961B1 (enExample)
MX (1) MX2013009279A (enExample)
PE (1) PE20140999A1 (enExample)
PH (1) PH12013501665A1 (enExample)
SG (1) SG192669A1 (enExample)
TW (1) TW201302736A (enExample)
UY (1) UY33905A (enExample)
WO (1) WO2012109415A1 (enExample)
ZA (1) ZA201306074B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (enExample) 2014-01-24 2018-02-24
BR112018067442A8 (pt) * 2016-02-12 2024-01-09 Pharmaxis Ltd Composto, composição farmacêutica, método de inibir a atividade da amina oxidase, método de tratar uma condição e uso de um composto
WO2023243601A1 (ja) 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
AU2002232558A1 (en) * 2000-12-12 2002-06-24 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な3−アミド−ピロロ[3,4−c]ピラゾール−5(1H,4H,6H)カルバルデヒド誘導体
EA201190235A1 (ru) * 2009-05-07 2012-05-30 Астразенека Аб Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
CN103491777A (zh) 2014-01-01
US20140364476A1 (en) 2014-12-11
US8841463B2 (en) 2014-09-23
EP2672821B9 (en) 2016-11-23
MA34961B1 (fr) 2014-03-01
UY33905A (es) 2012-08-31
ZA201306074B (en) 2014-04-30
IL227814A0 (en) 2013-09-30
CL2013002325A1 (es) 2014-01-03
EA201391155A1 (ru) 2014-01-30
KR20140048857A (ko) 2014-04-24
SG192669A1 (en) 2013-09-30
CN103491777B (zh) 2015-05-06
BR112013020510A2 (pt) 2016-07-12
DOP2013000182A (es) 2014-03-16
EP2672821B1 (en) 2016-04-20
NZ614540A (en) 2015-03-27
AR085163A1 (es) 2013-09-11
WO2012109415A1 (en) 2012-08-16
AU2012214405A1 (en) 2013-04-18
ES2583091T3 (es) 2016-09-19
US20130324584A1 (en) 2013-12-05
PE20140999A1 (es) 2014-09-11
JP5931929B2 (ja) 2016-06-08
AU2012214405B2 (en) 2015-07-23
JP2014506577A (ja) 2014-03-17
PH12013501665A1 (en) 2019-07-17
MX2013009279A (es) 2013-10-28
TW201302736A (zh) 2013-01-16
EP2672821A1 (en) 2013-12-18
US9187461B2 (en) 2015-11-17
EP2672821A4 (en) 2014-08-06
EA023168B1 (ru) 2016-04-29
CA2827157A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
TR201816379T4 (tr) DNA-PK inhibitörleri.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CL2013001340A1 (es) Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades.
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
GT201400016A (es) Indazoles
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
WO2013052943A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
BR112014012892A2 (pt) agentes de reversão anticoagulantes
PE20141944A1 (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2